2018
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim TK, Herbst RS, Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends In Immunology 2018, 39: 624-631. PMID: 29802087, PMCID: PMC6066429, DOI: 10.1016/j.it.2018.05.001.Peer-Reviewed Original ResearchConceptsAnti-PD therapyLong-term survival benefitAvailable treatment regimensFraction of respondersSurvival benefitTumor immunityTumor-immune interactionsAdvanced cancerTreatment regimensCancer immunotherapyTumor regressionTherapyAccurate tissueSuch treatmentAdaptive resistancePatientsMolecular mechanismsTrue resistanceImmunotherapyRegimensRight targetCancerRespondersImmunityAppropriate interpretation
2014
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion On Therapeutic Targets 2014, 18: 1407-1420. PMID: 25331677, DOI: 10.1517/14728222.2014.955794.Peer-Reviewed Original ResearchConceptsPD-1 pathwayEarly clinical trialsClinical trialsTumor typesDeath-1 pathway inhibitorsPD-1 pathway inhibitionImmune escape mechanismsOngoing clinical trialsEarly-stage cancerTreatment of cancerCure rateLikely respondersCancer immunotherapyPreclinical dataAntineoplastic effectsTherapeutic targetPathway inhibitionPathway inhibitorCancer typesBiological rationaleCancer treatmentMonoclonal antibodiesEscape mechanismsUpcoming trialsTrials